

05 -15 -06

TM
CASE 4-30961B



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10
EV 72727390345
Express Mail Label Number

MAY 12, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

OKUNO ET AL.

APPLICATION NO: 10/807,736

FILED: MARCH 24, 2004

FOR: USE OF BISPHOSPHONIC ACIDS FOR TREATING
ANGIOGENESIS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references (asterisked) are of record in parent Application No. 09/989,577 filed November 20, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Donna A. Jackson
Attorney for Applicants
Reg. No. 48,152

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852

Date: 5/11/06

INFORMATION DISCLOSURE CITATION

B-5
Use several sheets if necessary

Sheet 1 of 4

ATTY. DOCKET NO.
4-30961B
APPLICATION NO.
10/807,736
APPLICANT
OKUNO ET AL.
FILING DATE
MARCH 24, 2004

Group
1614

MAY 12 2006

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	5,358,941*	10/25/94	Bechard et al.			
AB	4,608,368*	8/26/86	Blum et al.			
AC	5,866,556*	2/2/99	Heikkilae-Hoikka			
AD	6,416,964*	7/9/02	Rezka et al.			
AE	5,116,864*	5/26/92	March et al.			
AF	6,426,367*	7/30/02	Das			
AG	6,416,737*	7/9/02	Manolagas et al.			
AH	6,677,320*	1/13/04	Diederich et al.			
AI	4,814,326	3/21/89	Rosini et al.			
AJ	4,927,814	5/22/90	Gall et al.			
AK	4,067,971	1/10/78	Francis et al.			
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM	WO 99/38998*	8/5/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
AN	EP 0 998 934*	5/10/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
AO	WO 99/04773*	2/4/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
AP	WO 88/00829*	2/11/88	WO			<input type="checkbox"/>	<input type="checkbox"/>
AQ	WO 95/29679*	11/9/95	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Shipman, "Antitumor Activity...", Leuk. Lymphoma, Vol. 32, Nos. 1/2, pp. 129-138, (XP000980146), (1998)*
AS	Martodam, "The Effects of Dichloroethylene...", Calcif. Tissue Int., Vol. 35, Nos. 4-5, pp. 512-519, (XP000980229), (1983)*
AT	Steiner et al., "Angiostatic activity of pamidronate (APD) and clodronate (Cl ₂ MDP) in the chicken-chorioallantoic membrane assay--preliminary report," in Osteoclast Inhibition in the Management of Malignancy-Related Bone Disorders, An International Symposium held during the 15 th International Cancer Congress, Hamburg, Germany, August 1990, O.L.M. Bijvoet and A. Lipton (ed.)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30961B
APPLICATION NO.
10/807,736
APPLICANT
OKUNO ET AL.
FILING DATE
MARCH 24, 2004

Group
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BA						
BB						
BC						
BD						
BE						
BF						
BG						
BH						
BI						
BJ						
BK						
BL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
BM	EP 0 252 504	1/13/88	EP (English equiv. is U 4,927,814)			<input type="checkbox"/>	<input type="checkbox"/>
BN	GB 2312165	10/22/97	GB			<input type="checkbox"/>	<input type="checkbox"/>
BO	WO 99/29345	6/17/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
BP	WO 96/39150	12/12/96	WO			<input type="checkbox"/>	<input type="checkbox"/>
BQ	WO 96/05862A	2/29/96	WO			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BR	M. Wegener et al., "Effektive Schmerzreduktion bei intermittierender Applikation," Krankenhaus Arzt, Vol. 68(10), pp. 453-457 (1995)
BS	Bonabello et al., "Attività analgesica del disodio clodronato," Riv. It. Biol. Med. 17, pp. 1-4 (1997)
BT	Purohit et al., "High-dose intravenous pamidronate for metastatic bone pain," Br. J. Cancer, Vol. 70, pp. 554-558 (1994)

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30961B
APPLICATION NO.
10/807,736
APPLICANT
OKUNO ET AL.
FILING DATE
MARCH 24, 2004Group
1614EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Monk et al., "Remission of Psoriasis with Etidronate Treatment of Underlying Paget's Disease of Bone," Dermatologica, Vol. 174, pp. 128-131 (1987)
	DB	Marshall et al., "The Effect of Pamidronate on Lumbar Spine Bone Density and Pain in Osteoporosis Secondary to Systemic Mastocytosis," British Journal of Rheumatology, Vol. 36, pp. 393-396 (1997)
	DC	Steiner, "Bisphosphonates inhibit angiogenesis in the chick chorioallantoic membrane," Abstract #404, Proceedings of the American Association for Cancer Research, Vol. 37, pg. 58 (1996)
	DD	Diener, Clinical Review--"Bisphosphonates for controlling pain from metastatic bone disease," Am J Health-Syst Pharm., Vol. 53, pp. 1917-27 (1996)
	DE	Folkman, "Angiogenesis in cancer, vascular, rheumatoid and other disease," Nature Medicine, Vol. 1(1), pp. 27-31 (1995)
	DF	Matsunaga et al., "Angiotatin is negatively associated with coronary collateral growth in patients with coronary artery disease," Am J Physiol Heart Circ Physiol, Vol. 288, pp. H2042-H2046 (2005)
	DG	Gowda et al., "Treatment of refractory angina pectoris," International Journal of Cardiology, Vol. 101, pp. 1-7 (2005)
	DH	Oura et al., "Relief of Severe Pain by Pamidronate in a Case of Terminal Lung Carcinoma," Japanese Journal of Lung Cancer, Vol. 36(4), pp. 449-453 (1996)
	DI	
	DJ	
	DK	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30961B
APPLICATION NO.
10/807,736
APPLICANT
OKUNO ET AL.
FILING DATE
MARCH 24, 2004

Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BA						
BB						
BC						
BD						
BE						
BF						
BG						
BH						
BI						
BJ						
BK						
BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	BM	WO 96/16027	5/30/96	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 98/43987*	10/8/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BR	
BS	
BT	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.